Clovis warns of insolvency as Rubraca goes into reverse

Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca.

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer. 

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...

Janssen CAR-T is Priority Medicine in EU, and more

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

Tesaro stock rockets as rumours of Roche takeover abound

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.